Primary liver cancer in Georgia: Seven years’ experience following the launch of the Hepatitis C Elimination Program, 2015–2022
Rattachement africain : ge, us, Kenya. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Hepatitis C virus (HCV) infection is associated with hepatocellular carcinoma (HCC), the predominant form of primary liver cancer (PLC). In 2015, Georgia implemented the HCV Elimination Program to reduce high national prevalence. We analyzed linked national registry data to characterize primary liver cancer cases in Georgia and evaluate the burden and treatment patterns of HCV infection among affected individuals during the national HCV elimination program. Data from the Georgian Cancer Registry (GCR), the national Vital Registration System, and the HCV Elimination Program databases were linked to perform a descriptive analysis of adult PLC cases diagnosed between January 2015-December 2022 and examine trends in HCV infection and treatment among them. Of 1734 reported PLC cases, 72.0% were male with a median age of 63 years (IQR 56-70). Two-thirds presented with stage 3-4 liver cancer and 80.2% were deceased by the end of 2022. Screening for HCV among PLC cases rose from 14.0% in 2015 to 92.8% in 2022. Of 1389 tested, 785 (56.5%) were anti-HCV positive. Of these, 654 (83.3%) were confirmed to be HCV RNA or HCVcAg positive, 472 (72.2%) of which had advanced liver fibrosis or cirrhosis. Among 654 HCV RNA or HCVcAg positive individuals, 495 (75.7%) initiated HCV treatment, with 355 (71.7%) treated more than one year before their PLC diagnosis. Our analysis supports the known association between PLC and HCV infection in Georgia. The high proportion of PLC cases receiving HCV treatment prior to their liver cancer diagnosis highlights the need to establish routine post-treatment follow-up for cirrhotic patients to facilitate earlier detection of PLC and improve outcomes.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Primary liver cancer in Georgia: Seven years’ experience following the launch of the Hepatitis C Elimination Program, 2015–2022
- Date Crossref
- 28/04/2026
- Éditeur
- Public Library of Science (PLoS)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
National Center for Disease Control and Public Health pays non établi dans la noticeÉtablissement de santé
-
Abbott (United States) pays non établi dans la noticeEntreprise
-
Abbott Fund pays non établi dans la noticeOrganisation à but non lucratif
-
NeoGenomics (United States) pays non établi dans la noticeEntreprise
-
The University of Texas Medical Branch at Galveston pays non établi dans la noticeUniversité ou école supérieure
-
Centers for Disease Control and Prevention pays non établi dans la noticeOrganisme public
-
The Centers pays non établi dans la noticeOrganisation à but non lucratif
-
Centers for Disease Control and Prevention Kenya (code pays fourni par la source)Organisme public
-
Health Systems Global pays non établi dans la noticeInstitution
-
University of Georgia pays non établi dans la noticeUniversité ou école supérieure
-
Abbott Diagnostics pays non établi dans la noticeInstitution
-
Abbott Pandemic Defense Coalition pays non établi dans la noticeInstitution
National Center for Disease Control and Public Health, Abbott (United States) et Abbott Fund, avec 9 autres affiliations. Pays d’affiliation : Kenya.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.